SynthesisJournal of comparative effectiveness research2026

Network meta-analysis: relative clinical efficacy and safety of elafibranor versus seladelpar as second-line treatment for patients with primary biliary cholangitis.

David Jones et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.